Replimune Group (REPL) to Release Quarterly Earnings on Thursday

Replimune Group (NASDAQ:REPL - Get Free Report) is expected to be announcing its Q4 2025 earnings results before the market opens on Thursday, May 15th. Analysts expect Replimune Group to post earnings of ($0.75) per share for the quarter.

Replimune Group (NASDAQ:REPL - Get Free Report) last posted its quarterly earnings results on Wednesday, February 12th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.70) by ($0.09). On average, analysts expect Replimune Group to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Replimune Group Price Performance

Shares of NASDAQ REPL traded down $0.37 during trading on Tuesday, hitting $7.49. 74,323 shares of the company were exchanged, compared to its average volume of 895,740. The company has a market cap of $577.07 million, a price-to-earnings ratio of -2.44 and a beta of 0.68. The company has a debt-to-equity ratio of 0.14, a current ratio of 11.43 and a quick ratio of 11.43. Replimune Group has a 1 year low of $4.92 and a 1 year high of $17.00. The firm's fifty day moving average price is $9.27 and its 200 day moving average price is $11.45.

Analyst Upgrades and Downgrades

REPL has been the topic of a number of research reports. HC Wainwright raised their price objective on Replimune Group from $21.00 to $22.00 and gave the stock a "buy" rating in a report on Thursday, February 13th. BMO Capital Markets raised their target price on shares of Replimune Group from $18.00 to $27.00 and gave the company an "outperform" rating in a research note on Wednesday, January 22nd. Finally, JPMorgan Chase & Co. lifted their target price on shares of Replimune Group from $16.00 to $18.00 and gave the company an "overweight" rating in a report on Wednesday, February 26th. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $19.43.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.